TEMITOPE ADEDAPO: Open Payments
NPI 1932821022 · GREENBELT, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 26 payments from 7 companies in 2025. Trend: 2023 $53 · 2024 $379 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 12 | $143 |
| ABBVIE INC. | 6 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| TMS NeuroHealth Centers Inc. | 1 | $21 |
Products named: Qelbree, VRAYLAR, CAPLYTA, INGREZZA, FANAPT, REXULTI, TMS NeuroHealth Centers Inc..
Industry payments across MD — which companies pay providers there.
